Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.

Psoriasis is thought to be associated with an increased risk of lymphoma. We report here the first case of an aggressive primary cutaneous pleomorphic T-cell lymphoma in a patient with psoriasis. The 36-year-old patient, who had previously been treated successively with methotrexate, ciclosporin and etanercept, presented with rapidly growing nodules on the leg. A biopsy confirmed a stage IVa primary cutaneous pleomorphic T-cell lymphoma. Despite treatment with pegylated liposomal doxorubicin, the disease progressed and the patient died 5 months later. This case of pleomorphic T-cell lymphoma was remarkable in both its extremely rapid onset and the aggressive nature of the disease. The onset of this disease in a patient with psoriasis who had been previously treated with immunosuppressive drugs and a tumour necrosis factor (TNF)-α blocker is of major interest. Only eight cases of cutaneous lymphomas associated with treatment with TNF-α blockers have been published previously. Most of these eight cases related to anti-TNFα antibodies; only two were linked to etanercept.

[1]  J. Krueger,et al.  New insights in the immunologic basis of psoriasis. , 2010, Seminars in cutaneous medicine and surgery.

[2]  F. Tubach,et al.  Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry , 2009, Annals of the rheumatic diseases.

[3]  S. Piana,et al.  Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  M. Pittelkow,et al.  Fatal cytotoxic cutaneous lymphoma presenting as ulcerative psoriasis. , 2009, Archives of dermatology.

[5]  M. Lebwohl,et al.  Treatments for psoriasis and the risk of malignancy. , 2009, Journal of the American Academy of Dermatology.

[6]  V. Costes,et al.  Subcutaneous panniculitis‐like T‐cell lymphoma in a patient receiving etanercept for rheumatoid arthritis , 2009, The British journal of dermatology.

[7]  Philippe Lafaille,et al.  Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. , 2009, Archives of dermatology.

[8]  F. O'Valle,et al.  [Methotrexate-associated lymphoproliferative disorder presenting as oral ulcers in a patient with rheumatoid arthritis]. , 2009, Actas dermo-sifiliograficas.

[9]  J. Cerhan,et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. , 2008, Blood.

[10]  J. Olsen,et al.  Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. , 2008, Arthritis and rheumatism.

[11]  S. Sarna,et al.  Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. , 2008, Acta dermato-venereologica.

[12]  B. N. Akay,et al.  Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. , 2007, Journal of drugs in dermatology : JDD.

[13]  A. Gottlieb,et al.  Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. , 2007, Archives of dermatology.

[14]  F. Wolfe,et al.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. , 2007, Arthritis and rheumatism.

[15]  J. Dauendorffer,et al.  Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis , 2007, The British journal of dermatology.

[16]  J. Seykora,et al.  Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. , 2007, Journal of the American Academy of Dermatology.

[17]  Daniel B. Shin,et al.  The risk of lymphoma in patients with psoriasis. , 2006, The Journal of investigative dermatology.

[18]  A. Silman,et al.  Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis , 2005, Annals of the rheumatic diseases.

[19]  M. Duvic,et al.  Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. , 2006, Clinical lymphoma & myeloma.

[20]  L. Thomas,et al.  Mycosis fungoides‐associated follicular mucinosis under adalimumab , 2005, The British journal of dermatology.

[21]  D. Gladman,et al.  An international cohort study of cancer in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[22]  T. Rüdiger,et al.  Medical history and risk for lymphoma: results of a population-based case-control study in Germany. , 2005, European journal of cancer.

[23]  T. Kupper,et al.  Aggressive cutaneous T-cell lymphomas after TNFα blockade , 2004 .

[24]  P. Boyle,et al.  Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women , 2004, Cancer Causes & Control.

[25]  J. Fraumeni,et al.  Leukemia, lymphoma, and multiple myeloma following selected medical conditions , 1992, Cancer Causes & Control.

[26]  T. Kupper,et al.  Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. , 2004, Journal of the American Academy of Dermatology.

[27]  D. Margolis,et al.  Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. , 2003, Archives of dermatology.

[28]  E. Mahé,et al.  CD30+ T‐cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab , 2003, The British journal of dermatology.

[29]  M. Corazza,et al.  Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine , 2003, Dermatology.

[30]  Jean Kanitakis,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[31]  W. Ahrens,et al.  Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. , 2003, European journal of cancer.

[32]  L. Dubertret,et al.  Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. , 2003, The Journal of investigative dermatology.

[33]  X. Mariette,et al.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. , 2002, Blood.

[34]  C. Owen,et al.  Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. , 2002, Journal of the American Academy of Dermatology.

[35]  P. Boffetta,et al.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. , 2001, The Journal of investigative dermatology.

[36]  D. Margolis,et al.  The risk of malignancy associated with psoriasis. , 2001, Archives of dermatology.

[37]  B. Moulin,et al.  Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[38]  A. Hannuksela-Svahn,et al.  Psoriasis, its treatment, and cancer in a cohort of Finnish patients. , 2000, The Journal of investigative dermatology.

[39]  S. Franceschi,et al.  Medical history and risk of Hodgkin's and non‐Hodgkin's lymphomas , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[40]  G. Frentz,et al.  Malignant tumours and psoriasis: a follow‐up study , 1999, The British journal of dermatology.

[41]  R. Stern,et al.  Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. , 1997, The Journal of investigative dermatology.

[42]  J. English,et al.  Long‐term efficacy and safety of cyclosporin in severe adult atopic dermatitis , 1997, The British journal of dermatology.

[43]  J. Karvonen,et al.  Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. , 1996, Journal of the American Academy of Dermatology.